<p>隨着全球市場在不斷變化的貿易政策和貨幣調整中航行，亞洲市場憑藉其多樣的經濟活動和強勁的股票表現繼續吸引關注。在這樣的背景下，雖然 “便士股票” 是一個較老的術語，但仍然是投資者尋求小型或新興公司潛在增長的焦點。通過識別那些財務健康狀況良好的公司，投資者可以發現平衡風險與潛在回報的機會。</p>
<h3>亞洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.30</td>
<td>THB4.25B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$2.86</td>
<td>HK$2.33B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.48</td>
<td>HK$915.41M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.52</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>China Sunsine Chemical Holdings (SGX:QES)</td>
<td>SGD0.68</td>
<td>SGD648.3M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.88</td>
<td>SGD11.33B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.95</td>
<td>THB1.4B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Rojana Industrial Park (SET:ROJNA)</td>
<td>THB4.82</td>
<td>THB9.74B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.55</td>
<td>SGD973.94M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲便士股票篩選器的 977 只股票完整列表。</p>
<p>讓我們回顧一些我們篩選出的顯著股票。</p>
<h2>嘉華國際控股 (SEHK:173)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 嘉華國際控股有限公司是一家投資控股公司，涉及香港和中國大陸的房地產開發和投資，市值約為 HK$77.9 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自中國大陸的房地產開發（HK$59.1 億）和香港（HK$5.4049 億），以及房地產投資產生的 HK$6.4297 億。</p>
<p><strong>市值：</strong> HK$77.9B</p>
<p>嘉華國際控股的市值為 HK$77.9 億，主要收入來自中國大陸和香港的房地產開發。過去五年中，它成功降低了債務與股本比率，保持了相對滿意的淨債務水平。公司的短期資產顯著超過其短期和長期負債，反映出強勁的流動性。然而，最近的收益急劇下降了 58.2%，預測未來三年將進一步下降。儘管交易價格低於估計的公允價值，但其股本回報率仍然較低，僅為 0.9%，由於不穩定的記錄，股息穩定性也不確定。</p>
<ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解嘉華國際控股的動態。</li>
<li>在這裏瞭解嘉華國際控股的未來增長軌跡。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis"/></p>
<p>SEHK:173 財務狀況分析截至 2025 年 8 月</p>
<h2>中國山水水泥集團 (SEHK:691)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 中國山水水泥集團有限公司是一家投資控股公司，在中華人民共和國製造和銷售水泥、熟料、混凝土及相關產品和服務，市值為 HK$38.3 億。</p>
<p><strong>運營：</strong> 該公司通過製造和交易水泥、熟料和混凝土的業務產生了 CN¥135 億的收入。</p>
<p><strong>市值：</strong> HK$38.3B</p>
<p>中國山水水泥集團最近的股價波動反映了該行業面臨的更廣泛挑戰。儘管去年實現盈利，但其收益受到大額一次性項目和銷售下降的影響，最近半年的收入為 CN¥55.5 億，而之前為 CN¥65.7 億。該公司在同一時期報告了 CN¥2.5 億的淨虧損，但相比去年更大虧損有所改善。其債務管理謹慎，淨債務與股本比率為 13.2%，儘管短期負債超過資產，面臨潛在流動性問題，尤其是在持續的法律問題和治理變更中。</p>
<ul>
<li>點擊這裏通過我們的詳細分析財務健康報告瞭解中國山水水泥集團的細微差別。</li>
<li>探索歷史數據，以跟蹤中國山水水泥集團的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis"/></p>
<p>SEHK:691 債務與股本歷史及分析截至 2025 年 8 月</p>
<h2>福安藥業 (集團) (SZSE:300194)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 福安藥業（集團）有限公司從事化學藥品的研究、開發、生產和銷售，市值為 CN¥58.5 億。</p>
<p><strong>運營：</strong> 該公司在製藥行業部門產生了 CN¥20.5 億的收入。</p>
<p><strong>市值：</strong> CN¥58.5B</p>
<p>福安藥業（集團）有限公司在低價股領域提供了穩定的投資概況，其製藥業務收入為 20.5 億人民幣，市值為 58.5 億人民幣。公司擁有經驗豐富的管理層和董事會，平均任期分別為 14.3 年和 3.7 年，支持戰略的連續性。短期資產充足覆蓋短期和長期負債，而運營現金流也能充分覆蓋 20% 的債務義務。儘管去年盈利增長為負，但利潤率從 9.7% 提高至 11%，顯示出在更廣泛的製藥行業環境挑戰中運營的韌性。</p>
<ul>
<li>點擊這裏查看福安藥業（集團）的全面資產負債表健康報告。</li>
<li>通過我們的公司歷史業績報告，深入瞭解福安藥業（集團）過去的趨勢和表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis"/></p>
<p>SZSE:300194 財務狀況分析截至 2025 年 8 月</p>
<h2>抓住機會</h2>
<ul>
<li>點擊開始探索其餘 974 只亞洲低價股。</li>
<li>對其他可能性感興趣？稀土金屬是大多數高科技設備、軍事和防禦系統以及電動車的原材料。全球競賽正在進行，以確保這些關鍵礦物的供應。搶先發現這 27 只稀土金屬股票，它們是為數不多的開採這一重要戰略資源的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

山水水泥

福安藥業

<p>亞洲市場正吸引投資者的關注，因為在貿易政策和貨幣調整變化的背景下，投資者開始關注低價股。值得注意的低價股包括嘉華國際控股、中國山水水泥集團和福安藥業（集團），它們的市值和財務健康評級各不相同。嘉華的市值為 77.9 億港元，但面臨盈利下降的問題。中國山水的市值為 38.3 億港元，價格波動較大，並且最近出現了淨虧損。福安藥業的估值為 58.5 億人民幣，儘管盈利增長為負，但顯示出運營韌性</p>

<p>As global markets navigate a landscape marked by shifting trade policies and monetary adjustments, the Asian market continues to capture attention with its diverse economic activities and robust stock performances. Amidst this backdrop, penny stocks—though an older term—remain a focal point for investors seeking potential growth in smaller or newer companies. By identifying those with strong financial health, investors can uncover opportunities that balance risk with promising returns.</p>
<div class="lb-trans"><p>隨着全球市場在不斷變化的貿易政策和貨幣調整中航行，亞洲市場憑藉其多樣的經濟活動和強勁的股票表現繼續吸引關注。在這樣的背景下，雖然 “便士股票” 是一個較老的術語，但仍然是投資者尋求小型或新興公司潛在增長的焦點。通過識別那些財務健康狀況良好的公司，投資者可以發現平衡風險與潛在回報的機會。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亞洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.30</td>
<td>THB4.25B</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$2.86</td>
<td>HK$2.33B</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.48</td>
<td>HK$915.41M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.52</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>China Sunsine Chemical Holdings (SGX:QES)</td>
<td>SGD0.68</td>
<td>SGD648.3M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.88</td>
<td>SGD11.33B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.95</td>
<td>THB1.4B</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Rojana Industrial Park (SET:ROJNA)</td>
<td>THB4.82</td>
<td>THB9.74B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.55</td>
<td>SGD973.94M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.30</td>
<td>THB4.25B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$2.86</td>
<td>HK$2.33B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.48</td>
<td>HK$915.41M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.52</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>China Sunsine Chemical Holdings (SGX:QES)</td>
<td>SGD0.68</td>
<td>SGD648.3M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.88</td>
<td>SGD11.33B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.95</td>
<td>THB1.4B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Rojana Industrial Park (SET:ROJNA)</td>
<td>THB4.82</td>
<td>THB9.74B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.55</td>
<td>SGD973.94M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 977 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲便士股票篩選器的 977 只股票完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些我們篩選出的顯著股票。</p>
</div><h2>K. Wah International Holdings (SEHK:173)</h2>
<div class="lb-trans"><h2>嘉華國際控股 (SEHK:173)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> K. Wah International Holdings Limited is an investment holding company involved in property development and investment in Hong Kong and Mainland China, with a market capitalization of approximately HK$7.79 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 嘉華國際控股有限公司是一家投資控股公司，涉及香港和中國大陸的房地產開發和投資，市值約為 HK$77.9 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from property development in Mainland China (HK$5.91 billion) and Hong Kong (HK$540.49 million), along with property investment generating HK$642.97 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自中國大陸的房地產開發（HK$59.1 億）和香港（HK$5.4049 億），以及房地產投資產生的 HK$6.4297 億。</p>
</div><p><strong>Market Cap:</strong> HK$7.79B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$77.9B</p>
</div><p>K. Wah International Holdings, with a market capitalization of HK$7.79 billion, derives substantial revenue from property development in Mainland China and Hong Kong. It has managed to reduce its debt-to-equity ratio over the past five years, maintaining a satisfactory net debt level relative to equity. The company's short-term assets significantly exceed both its short- and long-term liabilities, reflecting strong liquidity. However, recent earnings have declined sharply by 58.2%, with forecasts indicating further declines over the next three years. Despite trading below estimated fair value, its return on equity remains low at 0.9%, and dividend stability is uncertain due to an unstable track record.</p>
<div class="lb-trans"><p>嘉華國際控股的市值為 HK$77.9 億，主要收入來自中國大陸和香港的房地產開發。過去五年中，它成功降低了債務與股本比率，保持了相對滿意的淨債務水平。公司的短期資產顯著超過其短期和長期負債，反映出強勁的流動性。然而，最近的收益急劇下降了 58.2%，預測未來三年將進一步下降。儘管交易價格低於估計的公允價值，但其股本回報率仍然較低，僅為 0.9%，由於不穩定的記錄，股息穩定性也不確定。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of K. Wah International Holdings.</li>
<li>Learn about K. Wah International Holdings' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解嘉華國際控股的動態。</li>
<li>在這裏瞭解嘉華國際控股的未來增長軌跡。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/00d50ba3-cfe2-4d12-a839-d686c9f427be/chart/financial-position-analysis"/></p>
<p>SEHK:173 Financial Position Analysis as at Aug 2025</p>
<div class="lb-trans"><p>SEHK:173 財務狀況分析截至 2025 年 8 月</p>
</div><h2>China Shanshui Cement Group (SEHK:691)</h2>
<div class="lb-trans"><h2>中國山水水泥集團 (SEHK:691)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> China Shanshui Cement Group Limited is an investment holding company that manufactures and sells cement, clinker, concrete, and related products and services in the People's Republic of China, with a market cap of HK$3.83 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中國山水水泥集團有限公司是一家投資控股公司，在中華人民共和國製造和銷售水泥、熟料、混凝土及相關產品和服務，市值為 HK$38.3 億。</p>
</div><p><strong>Operations:</strong> The company generates CN¥13.50 billion in revenue from its operations in manufacturing and trading cement, clinker, and concrete.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過製造和交易水泥、熟料和混凝土的業務產生了 CN¥135 億的收入。</p>
</div><p><strong>Market Cap:</strong> HK$3.83B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$38.3B</p>
</div><p>China Shanshui Cement Group has seen a volatile share price recently, reflecting broader challenges in the sector. Despite becoming profitable last year, its earnings have been impacted by large one-off items and declining sales, with recent half-year revenue at CN¥5.55 billion compared to CN¥6.57 billion previously. The company reported a net loss of CN¥250 million for the same period but has improved from a larger loss last year. Its debt management is prudent with a satisfactory net debt to equity ratio of 13.2%, though short-term liabilities exceed assets, posing potential liquidity concerns amidst ongoing legal issues and governance changes.</p>
<div class="lb-trans"><p>中國山水水泥集團最近的股價波動反映了該行業面臨的更廣泛挑戰。儘管去年實現盈利，但其收益受到大額一次性項目和銷售下降的影響，最近半年的收入為 CN¥55.5 億，而之前為 CN¥65.7 億。該公司在同一時期報告了 CN¥2.5 億的淨虧損，但相比去年更大虧損有所改善。其債務管理謹慎，淨債務與股本比率為 13.2%，儘管短期負債超過資產，面臨潛在流動性問題，尤其是在持續的法律問題和治理變更中。</p>
</div><ul>
<li>Click here to discover the nuances of China Shanshui Cement Group with our detailed analytical financial health report.</li>
<li>Explore historical data to track China Shanshui Cement Group's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的詳細分析財務健康報告瞭解中國山水水泥集團的細微差別。</li>
<li>探索歷史數據，以跟蹤中國山水水泥集團的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/d39b267f-0948-43e9-811e-064b93c43341/chart/debt-equity-history-analysis"/></p>
<p>SEHK:691 Debt to Equity History and Analysis as at Aug 2025</p>
<div class="lb-trans"><p>SEHK:691 債務與股本歷史及分析截至 2025 年 8 月</p>
</div><h2>Fuan Pharmaceutical (Group) (SZSE:300194)</h2>
<div class="lb-trans"><h2>福安藥業 (集團) (SZSE:300194)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Fuan Pharmaceutical (Group) Co., Ltd. is engaged in the research, development, production, and sale of chemical drugs in China with a market cap of CN¥5.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 福安藥業（集團）有限公司從事化學藥品的研究、開發、生產和銷售，市值為 CN¥58.5 億。</p>
</div><p><strong>Operations:</strong> The company generates CN¥2.05 billion in revenue from its pharmaceutical industry segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司在製藥行業部門產生了 CN¥20.5 億的收入。</p>
</div><p><strong>Market Cap:</strong> CN¥5.85B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥58.5B</p>
</div><p>Fuan Pharmaceutical (Group) Co., Ltd. offers a stable investment profile within the penny stock segment, with its CN¥2.05 billion revenue from pharmaceuticals and a market cap of CN¥5.85 billion. The company boasts seasoned management and board teams, with average tenures of 14.3 and 3.7 years respectively, supporting strategic continuity. Short-term assets comfortably cover both short- and long-term liabilities, while operating cash flow adequately covers debt obligations at 20%. Despite negative earnings growth last year, profit margins improved to 11% from 9.7%, indicating operational resilience amid challenges in the broader pharmaceutical industry landscape.</p>
<div class="lb-trans"><p>福安藥業（集團）有限公司在低價股領域提供了穩定的投資概況，其製藥業務收入為 20.5 億人民幣，市值為 58.5 億人民幣。公司擁有經驗豐富的管理層和董事會，平均任期分別為 14.3 年和 3.7 年，支持戰略的連續性。短期資產充足覆蓋短期和長期負債，而運營現金流也能充分覆蓋 20% 的債務義務。儘管去年盈利增長為負，但利潤率從 9.7% 提高至 11%，顯示出在更廣泛的製藥行業環境挑戰中運營的韌性。</p>
</div><ul>
<li>Navigate through the intricacies of Fuan Pharmaceutical (Group) with our comprehensive balance sheet health report here.</li>
<li>Gain insights into Fuan Pharmaceutical (Group)'s past trends and performance with our report on the company's historical track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏查看福安藥業（集團）的全面資產負債表健康報告。</li>
<li>通過我們的公司歷史業績報告，深入瞭解福安藥業（集團）過去的趨勢和表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/c6ec26e1-4599-42f3-aeaf-88fd3c7a0b27/chart/financial-position-analysis"/></p>
<p>SZSE:300194 Financial Position Analysis as at Aug 2025</p>
<div class="lb-trans"><p>SZSE:300194 財務狀況分析截至 2025 年 8 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Click through to start exploring the rest of the 974 Asian Penny Stocks now.</li>
<li>Interested In Other Possibilities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊開始探索其餘 974 只亞洲低價股。</li>
<li>對其他可能性感興趣？稀土金屬是大多數高科技設備、軍事和防禦系統以及電動車的原材料。全球競賽正在進行，以確保這些關鍵礦物的供應。搶先發現這 27 只稀土金屬股票，它們是為數不多的開採這一重要戰略資源的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

亞洲市場亮點：2025 年 8 月值得關注的低價股